insights_auto
Pse është ulur 4142 6,62%?
Zhytu më thellëchevron_right
4142:TPE
Adimmune Corp
14,80 NT$
arrow_downward
-6,62%(-1,05) 1D
20 nën, 1:30:09 m.d., GMT+8 · TWD
search
Të gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për 4142...
Hap
15,75 NT$
I lartë
15,75 NT$
I ulët
14,80 NT$
Kapitalizimi i tregut
6,36 mld
Vëllimi mesatar
1,13 mln
Vëllimi
1,63 mln
Raporti çmim/fitim
85,76
Maksimumi 52-javor
21,50 NT$
Minimumi 52-javor
14,80 NT$
Fitimet për aksion
0,17 NT$
Aksionet në qarkullim
235,29 mln
Numri i punonjësve
564
Hap
15,75 NT$
I lartë
15,75 NT$
I ulët
14,80 NT$
Kapitalizimi i tregut
6,36 mld
Vëllimi mesatar
1,13 mln
Vëllimi
1,63 mln
Raporti çmim/fitim
85,76
Maksimumi 52-javor
21,50 NT$
Minimumi 52-javor
14,80 NT$
Fitimet për aksion
0,17 NT$
Aksionet në qarkullim
235,29 mln
Numri i punonjësve
564
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
The Motley Fool
·
3 orë më parë
The S&P 500 Has More Than Tripled in 10 Years, Even After Its Latest Pullback. Here’s What $1,000 in VOO Could Have Become.
Yahoo Finance
·
9 orë më parë
Dow and S&P 500 Plunge Into Correction as Tech Selloff Deepens
RealMoney Pro
·
4 orë më parë
The S&P 500’s Worst Week Since April 2025 Ends in a Correction
Marietta Daily Journal
·
5 orë më parë
S&P 500 sinks 3.7% and Nasdaq composite goes negative for the year as tech sell-off worsens
Profili
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
Rreth Adimmune Corp
Drejtori ekzekutiv-
Punonjësit564
Themeluar më1965
Selia-
SektoriHealth Care
Industria-
Uebsajtiadimmune.com.tw